Re­cur­sion and Bay­er to wind down fi­bro­sis R&D pact af­ter three years, re­fo­cus­ing on can­cer

Re­cur­sion Phar­ma­ceu­ti­cals and Bay­er re­worked a re­search pact to fo­cus on on­col­o­gy in­stead of fi­bro­sis as the Ger­man drug­mak­ing gi­ant homes in on can­cer un­der new CEO Bill An­der­son.

Bay­er be­came Re­cur­sion’s first Big Phar­ma part­ner when the two signed a five-year re­search deal in 2020 aim­ing to iden­ti­fy fi­bro­sis ther­a­pies. Now, more than three years lat­er, the two com­pa­nies said Thurs­day they will wind down the fi­bro­sis work that in­volved more than a dozen projects. Bay­er has yet to ex­er­cise any li­cens­es on lead se­ries or de­vel­op­ment can­di­dates from that fi­bro­sis re­search, ac­cord­ing to reg­u­la­to­ry fil­ings.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.